TrialCancer chemotherapy and pharmacology2022

Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.

Naoki Kotani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.